International Journal of Clinical Pharmacy

, Volume 41, Issue 1, pp 6–8 | Cite as

“Bite-sized” rivaroxaban patient education and its effect on knowledge

  • Jordan Sedlacek
  • Christopher Alan GiulianoEmail author
  • Kaitlin Baisden
  • Melissa Lipari
Short Research Report

Impacts on practice

  • The educational videos described and studied in this manuscript may be implemented in a hospital setting to improve patient knowledge regarding rivaroxaban.

  • Patient knowledge on rivaroxiban can be expected to improve immediately, after watching three educational videos, and be retained for at least seven days.


Adverse events related to oral anticoagulants were the top reason for emergency room visits in the United States from 2013 to 2014. Most of these visits were associated with warfarin (85.7%), although apixaban, dabigatran, and rivaroxaban were implicated as well [1]. Internationally, rivaroxaban demonstrated a major and nonmajor bleeding rate of 1.5 and 10.7%, therefore patient education of adverse events is essential [2]. To improve education on anticoagulants, a toolkit was released by the Institute of Safe Medicine Practices in 2017. The toolkit contains 23 recommendations surrounding patient education, including ensuring an appropriate reading...



The authors of this paper would like to thank Joshua Caballero, Pharm.D., BCPP, FCCP for providing insight that improved the manuscript.


This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflicts of interest

At the time of the project, the authors had no conflicts of interest to report.

Supplementary material

11096_2018_764_MOESM1_ESM.pdf (68 kb)
Supplementary material 1 (PDF 68 kb)


  1. 1.
    Shehab N, Lovegrove M, Geller A, Rose K, Weidle NJ, Budnitz DS, et al. US emergency department visits for outpatient adverse drug events, 2013–2014. JAMA. 2016;316(20):2115–25.CrossRefGoogle Scholar
  2. 2.
    Kirchhof P, Radaideh G, Kim YH, Lanas F, Haas S, Amarenco P, et al. Global prospective safety analysis of rivaroxaban. J Am Coll Cardiol. 2018;72(2):141–53.CrossRefGoogle Scholar
  3. 3.
    Institute for Safe Medicine Practices. ISMP medication safety self-assessment for antithrombotic therapy. 2017. Accessed 1 April 2018.
  4. 4.
    Tong W, Larsen ER, Armstrong AW. Videos to influence: a systematic review of effectiveness of video-based education in modifying health behaviors. J Behav Med. 2014;37(2):218–33.CrossRefGoogle Scholar
  5. 5.
    Friedman AJ, Cosby R, Boyko S, Hatton-Bauer J, Turnbull G. Effective teaching strategies and methods of delivery for patient education: a systematic review and practice guideline recommendations. J Cancer Educ. 2011;26(1):12–21.CrossRefGoogle Scholar
  6. 6.
    Ng A, Chan A, Ho V. Comprehension by older people of medication information with or without supplementary pharmaceutical pictograms. Appl Ergon. 2017;58:167–75.CrossRefGoogle Scholar
  7. 7.
    Sen M, Lee A, Tong L. Warfarin therapy video: impact on patient knowledge and preference of warfarin educational methods. Abstract presented at ASHP Midyear Clinical Meeting. Anaheim, CA; 2010.Google Scholar
  8. 8.
    Kim JJ, Mohammad R, Coley K, Donihi A. Use of an iPad to provide warfarin video education to hospitalized patients. J Patient Saf. 2015;11(3):160–5.CrossRefGoogle Scholar
  9. 9.
    Moore SJ, Blair EA, Steeb DR, Reed BN, Hull JH, Rodgers JE, et al. Impact of video technology on efficiency of pharmacist-provided anticoagulation counseling and patient comprehension. Ann Pharmacother. 2015;49(6):631–8.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Department of Clinical and Administrative SciencesLarkin University College of PharmacyMiamiUSA
  2. 2.Department of Pharmacy PracticeWayne State University and St. John Hospital and Medical CenterDetroitUSA
  3. 3.Department of Pharmacy, CS Mott Children’s HospitalMichigan MedicineAnn ArborUSA

Personalised recommendations